Funds

Discover Aescap's specialized biotech funds, our investment strategy and the investment process.

Select your fund

Two funds, one mission

The Aescap investment team offers investors access to the biotech and life sciences sector through two specialist funds, each with its own focus and risk profile. Each Aescap fund invests in approximately 20 publicly listed biotech and life sciences companies. Choose the fund that suits your investment objectives.

Since 2016

Aescap Life Sciences

Our flagship fund. Invests in publicly listed biotech and life sciences companies with distinct products and strong growth potential. Strong outperformance of its informal benchmark, the IBB (iShares Biotech ETF) in EUR.

More about this fund →
Since 2022

Aescap Genetics

Focused on gene, RNA, and cell therapy companies. Invests in the next generation of medicines that address the root cause of diseases.

More about this fund →
Fund selection

Which fund suits you best?

Each fund has its own focus, level of diversification and risk profile.

A quick chat is all it takes to help you on your way →
Aescap Life Sciences

Our flagship fund since 2016

The Aescap Life Sciences Fund invests in a concentrated portfolio of around 20 listed biotech and life sciences companies. Since its inception, the fund has significantly outperformed its informal benchmark, the iShares Biotech ETF (IBB) in EUR.

53%*
Outperformance vs. benchmark
±20
Companies in portfolio
20%
Gross return target per year
Go to the specific fund page →

* From launch in 2016 until 1 January 2026.

Aescap Genetics

The next generation of medicines

Aescap Genetics invests in companies at the forefront of gene, cell and RNA therapy. These companies are developing treatments that tackle the root cause of diseases rather than merely the symptoms.

Since its inception in 2022, the fund has outperformed its informal benchmark, the JPMorgan Genetics Fund EUR.

  • ±20 companies in a concentrated portfolio
  • Focus on genetics, gene therapy, cell, and RNA therapy
  • The fund manager is regulated by the AFM and DNB
Go to the specific fund page →
The next generation of medicines
Trusted

Governance & Supervision

The fund manager, Privium Fund Management BV, is regulated by the AFM and DNB and works exclusively with independent, specialist firms for custody and administration.

  • Custodian: Apex Depositary Services — responsible for the independent custody of the fund assets.
  • Administrator: IQEQ Financial Services — responsible for the independent NAV calculation, financial- and particpant administration.
  • Auditor: Forvis Mazars N.V. — responsible for the independent audit of the financial statements.
Governance & Supervision
Investing

Investing in an Aescap fund

The subscription process is straightforward. The Aescap funds operate on a (bi-)weekly entry and exit schedule.

1

Introductory meeting

Get in touch for a personal conversation. We explain our strategy, funds, and the investment process.

2

Receive documentation

You will receive the fund presentation, the prospectus and the application form.

3

Subscription and KYC

Once we have received your application form, we will assess whether you are eligible to participate in an Aescap fund in accordance with the KYC rules and regulations.

4

Deposit

Once you have received confirmation of your participation, please transfer the investment amount to the relevant fund’s account; for further details, please see the registration form.

5

Date of entry into the fund

On the next entry and exit date (bi-weekly), you enter the fund.

6

Reporting & communication

You will receive regular reports, newsletters and invitations to (virtual) investor meetings.

Schedule your introduction →
Next Gen

Investing for (grand)children

An increasing number of investors are choosing to invest in the Aescap funds on behalf of their children and grandchildren. Thanks to the long investment horizon, returns can benefit fully from the compound interest effect.

The Aescap investment team offers a special Next Gen programme for this purpose, whereby the assets are managed in the name of the child or grandchild. First- and second-degree relatives of existing investors can join the Next Gen programme from €10,000. An ideal way to start building wealth for your children or grandchildren early on in a sector with structural growth.

Sign up for Next Gen →
Investing for (grand)children
Documents

Fund documents

Download the relevant documents per fund. Contact us if you require additional information.

Aescap Life Sciences

Aescap Genetics

General

Ready to invest in the future of healthcare?

Get in touch for a personal conversation or subscribe to our newsletter.

Schedule an introductory meeting → Subscribe to our newsletter